Glioblastoma Treatment Success: One Year After ECCT and Targeted Therapy

Yuvena was unable to come when her father, Mr. Ben, consulted about her condition with ECCT medical team about a year ago. At that time, her right leg was too weak for her to walk outside the house. Her responses were slow, she often forgot what she wanted to say, her right eye was blurry, and she experienced frequent urination.

Now, her condition has returned to normal, she moves easily, speaks fluently, and her previous complaints such as blurred vision, nasal discomfort, headaches, and irregular menstruation have all disappeared.

At the end of July 2024, Yuvena suffered from severe headaches, motor disturbances, and speech difficulties. MRI and CT scan results revealed a tumor mass on the left side of her brain measuring about 7.8 x 6 cm with a cystic (fluid-filled) component, along with a solid portion measuring about 3.6 x 2.5 cm. The mass had already pressed into the right side of her brain by more than 1 cm, and there was also extensive bleeding in the left frontal region.

Her condition required urgent surgery to relieve the bleeding and remove the tumor mass. The surgery was performed at a hospital in her home country. The postoperative histology report confirmed that the tumor was a malignant glioblastoma, the most aggressive type of brain cancer, known for its extremely high recurrence rate. Therefore, after the surgery, she underwent about a month of radiation and chemotherapy. Her symptoms improved after surgery, her motor functions and speech recovered significantly.

However, the improvement did not last long. Less than a month after completing radiation and chemotherapy, her symptoms returned. MRI results taken a month later showed that the tumor mass had regrown, even larger than it had been before the surgery. Only the solid component was relatively smaller. The pressure on the right side of the brain had increased as well.

Treating glioblastoma remains a major challenge, as this type of cancer almost always recurs despite standard therapy, with recurrence rates around 90%. In Yuvena’s case, however, recurrence occurred much faster, within just one month, and the tumor had grown even larger than before surgery. This might be because the tumor was located in the brain’s communication center, where a more complete surgical removal would have risked permanent loss of speech. This made her case particularly difficult.

At her parents’ request, Yuvena began using ECCT (Electric Field Cancer Treatment) in early October 2024. At the same time, she continued routine check-ups and received targeted medication from her doctor in Malaysia.

Her response to ECCT combined with targeted therapy was relatively fast and considered Glioblastoma Treatment Success. MRI results after one month of ECCT use showed that the tumor mass had begun to shrink; both the solid portion and the flare (indicating inflammation and spread around the tumor) were relatively clear, and the midline shift toward the right brain had decreased. Yuvena’s symptoms improved even faster than the visible reduction in tumor size.

She continued to use the device regularly for about 1–2 hours twice daily. Yuvena continued routine follow-ups, MRI scans every three months, and targeted therapy in Malaysia. The MRI results consistently showed a gradual reduction in tumor mass.

After one year of treatment, Yuvena’s overall condition is nearly normal. Her latest MRI shows that the cystic mass has significantly reduced, the solid component remains clear with no recurrence, and the midline shift to the right side of the brain has completely disappeared.